|
|
|
01.10.25 - 20:12
|
Swiss Market Ends On Upbeat Note (AFX)
|
|
|
BRUSSELS (dpa-AFX) - The Switzerland market closed on an upbeat note on Wednesday, as pharma majors Roche and Novartis rallied sharply amid easing tariff concerns after Pfizer struck a deal with t......
|
|
|
01.10.25 - 18:00
|
Pharmanovia ernennt Stephan Eder zum Chief Executive Officer (Business Wire)
|
|
|
BASILDON, England--(BUSINESS WIRE)--Pharmanovia hat heute die Ernennung von Stephan Eder zum Chief Executive Officer (CEO) von Pharmanovia bekannt gegeben. Die Ernennung tritt mit sofortiger Wirkung in Kraft.
Stephan ist eine ausgesprochen erfahrene Führungskraft und hat im multi-nationalen Pharmasektor über zwei Jahrzehnte lang Teams und Unternehmen in hochrangigen Positionen geleitet. Zuletzt war er Mitglied des Executive Committee bei Stada, einem Private-Equity-finanzierten Unternehmen, dessen Schwerpunkt auf Generika, spezialisierten Präparaten und Verbrauchergesundheit liegt. Er bekleidete dort verschiedene Positionen im kaufmännischen Bereich, darunter die des Head of Europe, wo er ein Geschäftssegment mit einem Umsatz von 3,5 Milliarden Euro und über 6.000 Mitarbeitern leitete. Davor war Stephan bei Novartis tätig und wechselte später zu Sandoz und Hexal, wo er eine Reihe von Führungspositionen bekleidete, unter anderem die des CEO von Hexal/Sandoz Deutschland.
Guido Oelkers, Chair von Ph...
|
|
|
01.10.25 - 13:48
|
Big pharma is at war with the UK, and the government can′t back down now | Nick Dearden (The Guardian)
|
|
|
The industry has always wanted the NHS to pay more for its drugs; now it is pulling research and investment out of BritainThis year so far, some of the biggest pharmaceutical corporations in the world have withdrawn about £2bn in proposed investment from the UK. One has even threatened to withhold new medicines from NHS patients. Taken together, it's hard not to conclude that big pharma is at war with the UK.Merck has scrapped a £1bn research facility, while AstraZeneca ditched a £450m vaccine lab and is rethinking an expansion of another research unit. Bristol Myers Squibb (BMS) has cancelled 34 partnerships with the NHS in the last year, and Eli Lilly, Sanofi and Novartis are all believed to have put investments “on hold”. BMS is also threatening to play hardball with its new schizophrenia drug, saying it is “prepared to make the difficult decision” to “walk away” if the NHS won't pay the price the corporation wants to charge.Nick Dearden is director of Global Justice Now (formerly Worl...
|
|
|
01.10.25 - 13:36
|
FDA approves Novartis′ Rhapsido for CSU treatment (PBR)
|
|
|
The oral treatment was approved for use on those who continue to experience symptoms despite receiving H1 antihistamine therapy. Rhapsido is administered in pill form twice daily and
The post FDA approves Novartis' Rhapsido for CSU treatment appeared first on Pharmaceutical Business review....
|
|
|
01.10.25 - 13:03
|
Immatics Appoints Venkat Ramanan as Chief Financial Officer (GlobeNewswire EN)
|
|
|
Houston, Texas and Tuebingen, Germany, October 1, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today announced the appointment of Venkat Ramanan, Ph.D., as Chief Financial Officer (“CFO”), effective immediately. Dr. Ramanan is a seasoned financial leader in the biopharmaceutical industry with over 25 years of experience at companies including Seagen, Gilead Sciences and Amgen. He brings deep financial expertise in facilitating successful product launches, establishing scalable operations in global markets and enabling corporate transactions. He joins Immatics from Anthos Therapeutics, a Novartis company, where he served as CFO. He will succeed Immatics' current CFO, Arnd Christ.“We are thrilled to welcome Venkat to Immatics as an accomplished and passionate biopharmaceutical leader. His extensive experience will be instrumental in enabling us to continue to advance our PR...
|
|
|
01.10.25 - 11:42
|
AKTIEN IM FOKUS 2: US-Deal mit Pfizer hilft gesamter Pharmabranche (DPA-AFX)
|
|
|
Nach Darstellung von Trump sollen weitere Vereinbarungen mit anderen Pharmagesellschaften folgen. Der Deal von Pfizer könnte einen Weg für die Konkurrenz aufzeigen, im Gegenzug für deutliche Preissenkungen Schlimmeres zu verhindern, kommentierte Evan Seigerman von BMO Capital Markets. Als bemerkenswert hob ein weiterer Analyst hervor, dass Pfizer in der Pressemitteilung zu der Einigung keinerlei Auswirkungen auf die Finanzkennziffern und den Ausblick erwähnt habe. Die Pfizer-Aktien legten nach der Einigung mit Trump am Dienstag um 6,8 Prozent zu. Im Gegenzug der Preisermäßigungen für Medicaid werden die neuen US-Branchenzölle für den Konzern für drei Jahre ausgesetzt...
|
|
|
01.10.25 - 11:12
|
Pharmanovia Appoints Stephan Eder as Chief Executive Officer (Business Wire)
|
|
|
BASILDON, England--(BUSINESS WIRE)--Pharmanovia today announced the appointment of Stephan Eder as Chief Executive Officer (CEO) of Pharmanovia, effective today.
Stephan is a highly experienced leader, with over two decades leading teams and businesses in senior roles in multi-national pharma. Most recently, he served on the Executive Committee at Stada, a private equity backed company focusing on Generics, Specialty and Consumer Healthcare, in several commercial roles, most importantly as Head of Europe, leading a business with sales of EUR 3.5bn and over 6,000 employees. Prior to that, Stephan worked at Novartis and latterly moved over to Sandoz and Hexal, where he held a number of senior positions including CEO, Hexal/Sandoz Germany.
Guido Oelkers, Chair of Pharmanovia, commented: “Stephan has a strong track record delivering sustainable growth across diverse businesses. He has demonstrated a high degree of ambition and urgency and is passionate about building strong teams.
“The board welcomes Step...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
